新科学想法 › 文献管理 › 浏览文献

Can we prevent immunogenicity of human protein drugs?

cyzhgt 添加于 2011-12-12 11:11 | 1137 次阅读 | 0 个评论

作者
Scott DW, De Groot AS
摘要
Monoclonal antibodies have proved to be extremely valuable additions to conventional treatment for rheumatic diseases. However, despite the general trend towards "humanisation", these drugs remain immunogenic in clinical settings, baffling drug developers. In principle, humanised and fully human monoclonal antibodies are "self" immunoglobulins and should be tolerated. In this overview, the factors that may influence this process, the nature of immunogenicity and methods to analyse and modify potential immunogenicity are discussed. Finally, novel approaches to "re-induce" immunological tolerance to these proteins, including gene therapy and the recognition of unique regulatory epitopes, are outlined.
详细资料
- 文献种类:期刊
- 期刊名称: Annals of the Rheumatic Diseases
- 期刊缩写: Ann Rheum Dis
- 期卷页: 2010年第69 Suppl 1卷 i72-76页
- 地址: Department of Surgery, Microbiology, University of Maryland School of Medicine, Center for Vascular and Inflammatory Diseases, 800 West Baltimore St, Baltimore, MD 21201, USA. davscott@som.umaryland.edu
- ISBN: 0003-4967
- 备注:PMID:19995750
相关链接 DOI URL
cyzhgt 的文献笔记订阅